InsCorp, Inc. Reports Results for 3Q26

(OTCQX:IBTN) InsCorp, Inc. reported third quarter 2026 results, with revenue growth of 12% year-over-year for 3Q26. Fully diluted earnings per share (EPS) were $0.73 in 3Q26, compared to $0.72 in 2Q26 and $0.76 in 3Q25; excluding a federal tax credit purchase in 3Q25, EPS was $0.66 in 3Q25. The company declared a cash dividend of $0.12 per common share for 4Q26, payable December 4, 2026, to shareholders of record on November 13, 2026. The annualized dividend rate of $0.48 per share is a 9% increase from $0.44 per share paid in 2025. Average earning assets grew 13% year-over-year, or $121 million, with average loan growth of 14% ($112 million) and average deposit growth of 9% in 3Q26. Excluding the Murfreesboro expansion, average earning assets, loans, and deposits increased 8%, 7%, and 4% year-over-year, respectively. Murfreesboro team deposit and loan balances were $55.8 million and $67.6 million at 3Q26-end, up from $36.3 million and $50.3 million at 2Q26-end, and $27.5 million and $22.9 million at 4Q25-end. The Murfreesboro expansion affected EPS by ($0.02) in 3Q26, $0.01 in 2Q26, ($0.06) in 1Q26, and ($0.15) in 2025. Noninterest bearing and money market balances represented 84% of Murfreesboro deposits. Pre-provision pretax income (PPNR) grew 12% year-over-year to $3.1 million in 3Q26, with PPNR improving 20% annualized in the quarter. Net interest income grew 12% year-over-year and 9% LQA in 3Q26. Noninterest income increased 8% year-over-year to $455,000, driven by a 42% increase in deposit account service charges to $121,000. Noninterest expense grew 11% year-over-year, with personnel expense up 12% year-over-year (18% LQA). Excluding Murfreesboro costs, noninterest expense growth was 7% year-over-year. Noninterest expense was 2.09% of average assets in 3Q26; excluding Murfreesboro, it was 1.99%. Medquity, INSBANK's healthcare division, originated $29 million of loans in 3Q26, compared to $15 million in 2Q26 and an average of $33 million over the trailing twelve months. Medquity's portfolio grew 17% year-over-year (flat LQ) in 3Q26. Deposit growth was 14% year-over-year, with interest-bearing transaction balances up 64% year-over-year. Non-maturity deposit balances increased 46% year-over-year, making up 54% of deposits, up from 49% a quarter ago and 42% a year ago. CD balances declined 10% year-over-year and 11% LQ, now 46% of deposits, down from 51% a quarter ago and 58% a year ago. The loan-to-deposit ratio was 100% versus 97% a year ago. The net interest margin (NIM) was 3.18% in 3Q26, unchanged from 2Q26 and compared to 3.20% in 3Q25. Loan yield was 6.56% in 3Q26, down from 6.64% in 2Q26 and 6.79% in 3Q25. The yield on securities and short-term liquidity was 4.48% in 3Q26. The cost of deposits and cost of funds improved 15 bps and 17 bps year-over-year to 3.21% and 3.32%, respectively. Net chargeoffs were 0.00% of average loans annualized in 3Q26. Nonperforming loans and 90-day past dues were 0.32% of loans at 3Q26-end, up from 0.25% a quarter ago and down from 0.84% a year ago. Loans 30-89 days past due were 0.12% of loans at 3Q26-end. The allowance for credit losses was 1.25% of loans, representing 394% of NPLs. Tier-1 leverage, common equity tier-1, and total risk-based capital ratios were 10.21%, 10.83%, and 12.02% at quarter-end. Tangible common equity ratio was 7.04% at 3Q26-end, down from 8.14% a year ago. Tangible book value per share decreased 1% year-over-year to $26.20 as of September 30, 2026. C&D and CRE balances represented 85% and 328% of total risk-based capital, respectively. Accumulated Other Comprehensive Income was ($5.4 million), or 4.9% of bank-level Tier 1 capital of $111.5 million, as of September 30, 2026. The company has not repurchased shares in 2026, but repurchased 59,000 shares (2.0% of prior year-end shares) in 2025. The current repurchase program authorizes up to 100,000 shares (3.4% of outstanding shares) through January 25, 2028. Key executives quoted include Jim Rieniets (President and CEO), Billie Jo Parker (Chief Banking Officer), Scott Gupton (Chief Operating Officer), Blake Wilson (President of Medquity), Andrew Smith (Chief Deposit Officer), and Peyton Green (Chief Financial Officer).

InsCorp, Inc. Reports Results for 2Q26

(OTCQX:IBTN) InsCorp, Inc. reported fully diluted earnings per share ("EPS") of $0.72 in 2Q26 compared to $0.63 in 1Q26 and $0.71 in 2Q25. The company declared a cash dividend of $0.12 per common share for 3Q26, with an annualized quarterly dividend rate of $0.48 per share, representing an increase of 9% compared to $0.44 per share paid in 2025. Average earning asset growth was 16% year-over-year (Y/Y), or $139 million, with average loan growth of 13% Y/Y ($107 million) and average deposit growth of 15% Y/Y ($116 million) in 2Q26. Net interest income increased 14% Y/Y to $8.1 million in 2Q26 versus $7.1 million in 2Q25, while noninterest income dropped by $257,000 Y/Y to $337,000 in 2Q26. The loan-to-deposit ratio was 100% at 2Q26-end, and the tangible book value per share increased by 4% Y/Y to $26.57 as of June 30, 2026. The Board of Directors approved the payment of the quarterly dividend on September 4, 2026, to shareholders of record on August 14, 2026. The company projects that the net interest margin (NIM) is projected to gradually increase from the current level, assuming no change to the Fed Funds target rate and a static balance sheet.

InsCorp, Inc. Reports Results for 1Q26

InsCorp, Inc. (OTCQX:IBTN) reported first quarter 2026 results with EPS of $0.63, up 15% year-over-year from $0.55 in 1Q25. The company declared a cash dividend of $0.12 per share for 2Q26, with an annualized rate of $0.48, representing a 9% increase over 2025. Average earning assets grew 18% Y/Y, driven by deposit growth of 21% and loan growth of 13%. The Murfreesboro expansion contributed to strong deposit and loan growth, though it negatively impacted EPS by ($0.06) in 1Q26. Asset quality improved, with nonperforming loans dropping to 0.25% of loans and net chargeoffs at 0.00% in 1Q26.